Home » Stocks » NTRP

Neurotrope, Inc. (NTRP)

Stock Price: $0.941 USD -0.109 (-10.38%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $1.070 +0.129 (13.71%) Dec 1, 6:44 PM

Stock Price Chart

Key Info

Market Cap 22.39M
Revenue (ttm) n/a
Net Income (ttm) -12.35M
Shares Out 23.79M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $0.941
Previous Close $1.050
Change ($) -0.109
Change (%) -10.38%
Day's Open 1.040
Day's Range 0.915 - 1.040
Day's Volume 500,213
52-Week Range 0.713 - 1.470

More Stats

Market Cap 22.39M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 23.79M
Float n/a
EPS (basic) -0.64
EPS (diluted) -0.64
FCF / Share -0.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 46,336
Short Ratio 0.19
Short % of Float n/a
Beta 2.26
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.90
Revenue n/a
Operating Income -10.88M
Net Income -12.35M
Free Cash Flow -8.42M
Net Cash 27.00M
Net Cash / Share 1.13
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -27.73%
ROE -52.59%
ROIC -11,044.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$1.00*
Low
1.00
Current: $0.941
High
1.00
Target: 1.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-15.51-11.15-12.70-12.93-9.45-9.27-7.59
Net Income-15.13-11.02-12.62-12.92-9.44-9.25-7.59
Shares Outstanding12.998.057.712.270.840.690.68
Earnings Per Share-1.16-1.37-1.64-5.69-11.64-15.68-12.80
Operating Cash Flow-11.89-7.70-10.99-7.38-10.32-7.15-5.53
Capital Expenditures-0.01----0.01-0.05-
Free Cash Flow-11.89-7.70-10.99-7.38-10.33-7.21-5.53
Cash & Equivalents17.3828.8516.1125.7711.238.0115.21
Total Debt----0.01--
Net Cash / Debt17.3828.8516.1125.7711.228.0115.21
Assets17.9029.4816.4425.9712.788.1615.30
Liabilities0.482.961.562.3612.8119.8120.35
Book Value17.4226.5214.8923.60-0.02-11.65-5.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Neurotrope, Inc.
Country United States
Employees 5
CEO Charles S. Ryan

Stock Information

Ticker Symbol NTRP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NTRP

Description

Neurotrope, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.